Abstract:Neuraminidase (NA) is a pivotal surface enzyme and a key therapeutic target in combating the influenza A virus. Its evolution can lead to potential zoonotic transmission, seasonal epidemics, and the emergence of drug-resistant mutants. To gain comprehensive insights into the mutational effects and drug resistance profiles of NA, we employed a high-throughput profiling system to quantify the replication capacity of NA mutants at the single-nucleotide level in mouse lung tissues. The fitness of NA mutants is generally correlated with natural mutation occurrence and is constrained by both the requirement to maintain protein stability and NA function. Leveraging this system, we profiled the drug resistance to the three most commonly used neuraminidase inhibitors (NAIs): zanamivir, oseltamivir, and peramivir. In addition to identifying previously reported drug resistance mutations, we validated novel mutants. Notably, we identified an allosteric mutation that confers resistance to all three drugs, which may affect drug binding by interfering with the tetramerization of NA. Moreover, the fitness cost associated with drug-resistant mutations may limit their widespread dissemination. In summary, we provided a parallel characterization of NA's fitness and drug resistance landscape in an context, which may guide the rational selection of antiviral drugs for optimal therapeutic efficacy and second-generation NAI development. IMPORTANCE NA is a crucial surface antigen and drug target of influenza A virus. A comprehensive understanding of NA's mutational effect and drug resistance profiles is essential for comprehending the evolutionary constraints and making informed choices regarding drug selection to combat resistance in clinical settings. In the current study, we established an efficient deep mutational screening system in mouse lung tissues and systematically evaluated the fitness effect and drug resistance to three neuraminidase inhibitors of NA single-nucleotide mutations. The fitness of NA mutants is generally correlated with a natural mutation in the database. The fitness of NA mutants is influenced by biophysical factors such as protein stability, complex formation, and the immune response triggered by viral infection. In addition to confirming previously reported drug-resistant mutations, novel mutations were identified. Interestingly, we identified an allosteric drug-resistance mutation that is not located within the drug-binding pocket but potentially affects drug binding by interfering with NA tetramerization. The dual assessments performed in this study provide a more accurate assessment of the evolutionary potential of drug-resistant mutations and offer guidance for the rational selection of antiviral drugs.

The Mechanism by Which 146-N-glycan Affects the Active Site of Neuraminidase

Multivalent Interactions Between Fully Glycosylated Influenza Virus Hemagglutinins Mediated by Glycans at Distinct N-glycosylation Sites

Novel Binding Patterns Between Ganoderic Acids and Neuraminidase: Insights from Docking, Molecular Dynamics and Mm/Pbsa Studies

Intact Glycopeptide Analysis of Influenza A/H1N1/09 Neuraminidase Revealing the Effects of Host and Glycosite Location on Site‐Specific Glycan Structures

Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants

The 340-cavity in neuraminidase provides new opportunities for influenza drug development: A molecular dynamics simulation study.

Mutation-induced Spatial Differences in Neuraminidase Structure and Sensitivity to Neuraminidase Inhibitors

Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding

Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6

Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study

The Glycan‐mediated Mechanism on the Interactions of Gp120 with CD4 and Antibody: Insights from Molecular Dynamics Simulation

The calcium ion and conserved water molecules in neuraminidases: Roles and implications for substrate binding

N-Glycan Profiles of Neuraminidase from Avian Influenza Viruses

Insight into the Predictive Binding Modes of the Influenza a Neuraminidase in Complexes with Avian and Human Receptor Analogues

Discovery of Neuraminidase Inhibitors based on 3D-QSAR, Molecular Docking and MD Simulations

In Silico Study on Multidrug Resistance Conferred by I223r/H275y Double Mutant Neuraminidase

Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo .

Influenza neuraminidase operates via a nucleophilic mechanism and can be targeted by covalent inhibitors

Molecular Mechanism of the Enhanced Virulence of 2009 Pandemic Influenza A (H1N1) Virus from D222G Mutation in the Hemagglutinin: a Molecular Modeling Study

Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity

The Conformational Analysis and Proton Transfer of Neuraminidase Inhibitors: A Theoretical Study